Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | PRSS12 | P56730 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 8/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650995 | 0.95 | PRSS12 (0.47) | KDRPRSS12HDAC6CNR1CNR2 | |
| SCHEMBL5650474 | 0.92 | CNR1 (0.41) | KDRPRSS12CNR1CNR2RHEB | |
| SCHEMBL5652794 | 0.92 | PRSS12 (0.41) | KDRPRSS12HDAC6CNR1CNR2 | |
| SCHEMBL5653971 | 0.92 | AMY1A (0.42) | KDRPRSS12HDAC6CNR1CNR2 | |
| SCHEMBL5651818 | 0.89 | FOXO1 (0.42) | KDRPRSS12HDAC6CNR1CNR2 | |
| SCHEMBL5653630 | 0.88 | PRSS12 (0.54) | KDRPRSS12HDAC6RHEB | |
| SCHEMBL5652478 | 0.87 | HDAC6 (0.48) | HDAC6CNR1MEN1CYP1A2MAPT | |
| SCHEMBL5652578 | 0.87 | SIRT2 (0.42) | PRSS12CNR1CNR2MEN1MAPT | |
| SCHEMBL5652259 | 0.83 | PRSS12 (0.47) | KDRPRSS12HDAC6CNR1CNR2 | |
| SCHEMBL5650683 | 0.83 | RHEB (0.47) | PRSS12CNR1CNR2RHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | KDR 2994/4885PRSS12 979/4885HDAC6 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.